ClinicalTrials.gg
CompletedNCT05635838Updated Nov 1, 2024Results posted

Study to Evaluate of the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa

A Phase 2 interventional study of Ruxolitinib cream and Vehicle cream in Hidradenitis Suppurativa, sponsored by Incyte Corporation. Completed at 20 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-01.

Sponsored by Incyte Corporation · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
69
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Hidradenitis Suppurativa by Incyte Corporation — 3 open to participants now, 6 under way, 4 of them phase 3. Hidradenitis Suppurativa · Incyte Corporation.

Enrollment
8th of 12
69 · median 391
Started
2022
with 1 other
Phase 2
5 of 12
1 open now
Registered
6th of 12
by date

Among the 12 studies in Hidradenitis Suppurativa by Incyte Corporation, this one is the 8th largest by enrollment, is one of 2 that started in 2022, is one of 5 in phase 2, and was the 6th registered.

Hidradenitis Suppurativa

285 studies on the registry are indexed under Hidradenitis Suppurativa; 88 are open to participants now.

Browse Hidradenitis Suppurativa studies →

Open to participants now

3 of the 12 studies in Hidradenitis Suppurativa by Incyte Corporation are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 61 Hidradenitis Suppurativa studies recruiting now, 33 (54%) set no upper age limit and 17 (28%) stop at 75 or younger; 13 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Hidradenitis Suppurativa by Incyte Corporation, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of Ruxolitinib cream in participants with Hidradenitis Suppurativa. This is a randomized 16-week double-blind, vehicle-controlled (DBVC) study followed by a 16 week open label extension period (OLE) with an active treatment for participants who complete the DBVC period.

03

Conditions studied

  • Hidradenitis Suppurativa

Keywords

  • Hidradenitis suppurativa
  • skin disease
  • ruxolitinb cream
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of HS based on clinical history and physical examination for at least 3 months.
  • Diagnosis of HS (Hurley I or II) with the following:

    1. A total AN count of 3 to ≤ 10, with no draining tunnels at screening and baseline visits. AND
    2. The AN count at the screening AND baseline visits:
  • AN of 3 should affect at least 1 distinct anatomical area
  • AN of > 3 to ≤ 10 should affect at least 2 distinct anatomical areas.
  • Baseline Skin Pain or Itch NRS score ≥ 1.
  • Agreement to NOT use topical and systemic antibiotics for treatment of HS during the study.
  • Agreement to NOT use a diluted beach bath or topical antiseptic washes containing chlorhexidine gluconate or benzoyl peroxide on the areas affected by HS lesions during the study.
  • Willingness to avoid pregnancy or fathering children

Exclusion criteria

Exclusion Criteria:

  • Presence of draining tunnels at screening or at baseline visits.
  • Concurrent conditions and history of other diseases:

    1. Active ongoing inflammatory diseases of the skin other than HS that might confound the evaluation of HS.
    2. Any other concomitant skin disorder (eg, generalized erythroderma such as Netherton's syndrome), pigmentation, or extensive scarring that in the opinion of the investigator may interfere with the evaluation of HS AN or compromise participant safety.
    3. (eg, lymphoma, acquired immunodeficiency syndrome, or Wiskott-Aldrich syndrome).
    4. Chronic or acute infection requiring treatment with systemic antibiotics, antivirals, antiparasitics, antiprotozoals, or antifungals within 2 weeks before baseline.
    5. Active acute bacterial, fungal, or viral skin infection (eg, herpes simplex, herpes zoster, chicken pox, clinically infected AD, or impetigo) within 2 weeks before baseline.
  • Laboratory values outside of the protocol-defined criteria.
  • Use of any prohibited medications per protocol-defined criteria.
  • Pregnant or lactating participants, or those considering pregnancy during the period of their study participation.
  • Other exclusion criteria may apply.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
69 participants (actual)

Study arms

  • Experimental
    Ruxolitinib Cream

    Ruxolitinib 1.5% cream BID for 16 weeks of double-blind, vehicle-controlled (DBVC) period followed by ruxolitinb 1.5% cream BID for 16 weeks in an open-label extension.

    Drug: Ruxolitinib cream

  • Experimental
    Vehicle Cream

    Vehicle cream BID for 16 weeks of double-blind, vehicle-controlled (DBVC) period followed by ruxolitinb 1.5% cream BID for 16 weeks in an open-label extension.

    Drug: Vehicle cream

Interventions

  • Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.

    Also known as: INCB018424 cream

  • DrugVehicle cream

    Vehicle cream is matching in appearance to ruxolitinib cream and is to be applied in the same manner as ruxolitinib cream.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Abscess and Inflammatory Nodule (AN) Count at Week 16

    The mixed model repeated measure (MMRM) included the fixed effects of the treatment group (ruxolitinib 1.5% and vehicle cream), stratification factor (Baseline AN count of ≥3 to 4 or ≥5 to 10), visit, and visit-by-treatment interaction. Change from Baseline was calculated as the Week 16 value minus the Baseline value.

    Time frame: Baseline; Week 16

Secondary outcomes

  1. Percentage of Participants Achieving AN50, AN75, AN90, and AN100 at Week 16

    AN50, AN75, AN90, and AN100 were defined as at least a 50%, 75%, 90%, and 100% decrease, respectively, in AN count relative to Baseline.

    Time frame: Baseline; Week 16

  2. Change From Baseline to Week 16 in Total AN Count in Anatomical Areas With Pre-existing ANs at Baseline

    Pre-existing ANs at Baseline were defined as abscesses and/or inflammatory nodules present at Baseline. All new ANs identified during the study in an anatomical area that had pre-existing ANs at Baseline were counted. Any new ANs identified in an anatomical area that was initially free of ANs at Baseline were not counted. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. The MMRM included the fixed effects of the treatment group (ruxolitinib 1.5% and vehicle cream), stratification factor (Baseline AN count of ≥3 to 4 or ≥5 to 10), visit, and visit-by-treatment interaction. Change from Baseline was calculated as the Week 16 value minus the Baseline value.

    Time frame: Baseline; Week 16

  3. Change From Baseline in Skin Pain Numeric Rating Scale (NRS) Score at Week 16

    The Skin Pain NRS is a daily participant-reported measure (24-hour recall) of the worst level of skin pain related to Hidradenitis Suppurativa. The participants rated the pain severity of their Hidradenitis Suppurativa by selecting a number from 0 (no pain) to 10 (worst imaginable pain) that best described their worst level of pain in the past 24 hours. The MMRM included the fixed effects of the treatment group (ruxolitinib 1.5% and vehicle cream), stratification factor (Baseline AN count of ≥3 to 4 or ≥5 to 10), visit, and visit-by-treatment interaction. Change from Baseline was calculated as the Week 16 value minus the Baseline value.

    Time frame: Baseline; Week 16

  4. Change From Baseline in Itch NRS Score at Week 16

    The Itch NRS is a daily participant-reported measure (24-hour recall) of the worst level of itch intensity related to Hidradenitis Suppurativa. The participants rated the itch severity of their Hidradenitis Suppurativa by selecting a number from 0 (no itch) to 10 (worst imaginable itch) that best described their worst level of itching in the past 24 hours. The MMRM included the fixed effects of the treatment group (ruxolitinib 1.5% and vehicle cream), stratification factor (Baseline AN count of ≥3 to 4 or ≥5 to 10), visit, and visit-by-treatment interaction. Change from Baseline was calculated as the Week 16 value minus the Baseline value.

    Time frame: Baseline; Week 16

  5. Percentage of Participants Who Achieve Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 16

    HiSCR was defined as at least a 50% reduction in AN count with no increase in either abscess or draining fistula counts, relative to Baseline.

    Time frame: Baseline; Week 16

  6. Change From Baseline in the International Hidradenitis Suppurativa Severity Score System (IHS4) Score at Week 16

    The IHS4 is a composite, dynamic score and validated tool used to determine Hidradenitis Suppurativa severity. IHS4 score was calculated by the number of inflammatory nodules (multiplied by 1) plus the number of abscesses (multiplied by 2) plus the number of draining tunnels (multiplied by 4). Scores: mild=0-3; moderate=4-10; severe ≥11. The MMRM included the fixed effects of the treatment group (ruxolitinib 1.5% and vehicle cream), stratification factor (Baseline AN count of ≥3 to 4 or ≥5 to 10), visit, and visit-by-treatment interaction. Change from Baseline was calculated as the Week 16 value minus the Baseline value.

    Time frame: Baseline; Week 16

  7. Number of Participants With Any Treatment-emergent Adverse Event (TEAE ) in the Double-blind, Vehicle-controlled (DBVC) Period

    An adverse event (AE) was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it is considered drug related. An AE could therefore have been any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drug. A TEAE was defined as any AE reported for the first time or the worsening of a pre-existing event after the first application of study drug.

    Time frame: up to Week 16 plus 30 days

  8. Number of Participants With Any Grade 3 or Higher TEAE in the DBVC Period

    An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it is considered drug related. A TEAE was defined as any AE reported for the first time or the worsening of a pre-existing event after the first application of study drug. The severity of AEs was assessed using Common Terminology Criteria for Adverse Events (CTCAE) v5.0 Grades 1 through 5. Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; treatment not indicated. Grade 2: moderate; minimal, local, or noninvasive treatment indicated; limiting age-appropriate activities of daily living. Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4: life-threatening consequences; urgent treatment indicated. Grade 5: fatal.

    Time frame: up to Week 16 plus 30 days

  9. Number of Participants With Any TEAE in the Open-label Extension (OLE) Period

    An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it is considered drug related. An AE could therefore have been any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drug. A TEAE was defined as any AE reported for the first time or the worsening of a pre-existing event after the first application of study drug.

    Time frame: from Week 17 up to Week 32 plus 30 days

  10. Number of Participants With Any Grade 3 or Higher TEAE in the OLE Period

    An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it is considered drug related. A TEAE was defined as any AE reported for the first time or the worsening of a pre-existing event after the first application of study drug. The severity of AEs was assessed using CTCAE v5.0 Grades 1 through 5. Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; treatment not indicated. Grade 2: moderate; minimal, local, or noninvasive treatment indicated; limiting age-appropriate activities of daily living. Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4: life-threatening consequences; urgent treatment indicated. Grade 5: fatal.

    Time frame: from Week 17 up to Week 32 plus 30 days

07

Results

Posted Nov 1, 2024

Participant flow

16-Week DBVC Period
Participant flow — 16-Week DBVC Period
MilestoneDouble-blind, Vehicle-Controlled (DBVC) Period: Ruxolitinib 1.5% Cream BIDDBVC Period: Vehicle Cream BIDOpen-label Extension (OLE) Period: Ruxolitinib 1.5% Cream BIDOLE Period: Vehicle Cream to Ruxolitinib 1.5% Cream BID
Started343500
Completed243200
Not completed10300
Withdrew: Adverse event2000
Withdrew: Lost to follow-up5100
Withdrew: Physician decision0100
Withdrew: Protocol violation1000
Withdrew: Withdrawal by subject1000
Withdrew: Presence of disease tunnel1000
Withdrew: Developed draining fistula0100
16-Week OLE Period
Participant flow — 16-Week OLE Period
MilestoneDouble-blind, Vehicle-Controlled (DBVC) Period: Ruxolitinib 1.5% Cream BIDDBVC Period: Vehicle Cream BIDOpen-label Extension (OLE) Period: Ruxolitinib 1.5% Cream BIDOLE Period: Vehicle Cream to Ruxolitinib 1.5% Cream BID
Started002432
Completed002124
Not completed0038
Withdrew: Adverse event0002
Withdrew: Lost to follow-up0013
Withdrew: Physician decision0001
Withdrew: Protocol violation0011
Withdrew: Withdrawal by subject0001
Withdrew: Pregnancy0010

Outcome measures

PrimaryChange From Baseline in Abscess and Inflammatory Nodule (AN) Count at Week 16

The mixed model repeated measure (MMRM) included the fixed effects of the treatment group (ruxolitinib 1.5% and vehicle cream), stratification factor (Baseline AN count of ≥3 to 4 or ≥5 to 10), visit, and visit-by-treatment interaction. Change from Baseline was calculated as the Week 16 value minus the Baseline value.

Time frame:
Baseline; Week 16
Reported as:
Least squares mean · ANs
Change From Baseline in Abscess and Inflammatory Nodule (AN) Count at Week 16
ANsDouble-blind, Vehicle-Controlled (DBVC) Period: Ruxolitinib 1.5% Cream BIDDBVC Period: Vehicle Cream BID
Change From Baseline in Abscess and Inflammatory Nodule (AN) Count at Week 16-3.61 ± 0.378-2.42 ± 0.336
Statistical analysis
  • Double-blind, Vehicle-Controlled (DBVC) Period: Ruxolitinib 1.5% Cream BID vs DBVC Period: Vehicle Cream BID · ANCOVA · p = 0.0215 · Least squares mean difference: -1.20 · 95% CI -2.21 to -0.18
SecondaryPercentage of Participants Achieving AN50, AN75, AN90, and AN100 at Week 16

AN50, AN75, AN90, and AN100 were defined as at least a 50%, 75%, 90%, and 100% decrease, respectively, in AN count relative to Baseline.

Time frame:
Baseline; Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving AN50, AN75, AN90, and AN100 at Week 16
percentage of participantsDouble-blind, Vehicle-Controlled (DBVC) Period: Ruxolitinib 1.5% Cream BIDDBVC Period: Vehicle Cream BID
AN5079.256.3
AN7554.225.0
AN9020.812.5
AN10020.812.5
SecondaryChange From Baseline to Week 16 in Total AN Count in Anatomical Areas With Pre-existing ANs at Baseline

Pre-existing ANs at Baseline were defined as abscesses and/or inflammatory nodules present at Baseline. All new ANs identified during the study in an anatomical area that had pre-existing ANs at Baseline were counted. Any new ANs identified in an anatomical area that was initially free of ANs at Baseline were not counted. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. The MMRM included the fixed effects of the treatment group (ruxolitinib 1.5% and vehicle cream), stratification factor (Baseline AN count of ≥3 to 4 or ≥5 to 10), visit, and visit-by-treatment interaction. Change from Baseline was calculated as the Week 16 value minus the Baseline value.

Time frame:
Baseline; Week 16
Reported as:
Least squares mean · ANs
Change From Baseline to Week 16 in Total AN Count in Anatomical Areas With Pre-existing ANs at Baseline
ANsDouble-blind, Vehicle-Controlled (DBVC) Period: Ruxolitinib 1.5% Cream BIDDBVC Period: Vehicle Cream BID
Change From Baseline to Week 16 in Total AN Count in Anatomical Areas With Pre-existing ANs at Baseline-3.85 ± 0.362-3.17 ± 0.323
Statistical analysis
  • Double-blind, Vehicle-Controlled (DBVC) Period: Ruxolitinib 1.5% Cream BID vs DBVC Period: Vehicle Cream BID · ANCOVA · p = 0.1671 · Least squares mean difference: -0.68 · 95% CI -1.65 to 0.29
SecondaryChange From Baseline in Skin Pain Numeric Rating Scale (NRS) Score at Week 16

The Skin Pain NRS is a daily participant-reported measure (24-hour recall) of the worst level of skin pain related to Hidradenitis Suppurativa. The participants rated the pain severity of their Hidradenitis Suppurativa by selecting a number from 0 (no pain) to 10 (worst imaginable pain) that best described their worst level of pain in the past 24 hours. The MMRM included the fixed effects of the treatment group (ruxolitinib 1.5% and vehicle cream), stratification factor (Baseline AN count of ≥3 to 4 or ≥5 to 10), visit, and visit-by-treatment interaction. Change from Baseline was calculated as the Week 16 value minus the Baseline value.

Time frame:
Baseline; Week 16
Reported as:
Least squares mean · scores on a scale
Change From Baseline in Skin Pain Numeric Rating Scale (NRS) Score at Week 16
scores on a scaleDouble-blind, Vehicle-Controlled (DBVC) Period: Ruxolitinib 1.5% Cream BIDDBVC Period: Vehicle Cream BID
Change From Baseline in Skin Pain Numeric Rating Scale (NRS) Score at Week 16-1.90 ± 0.532-2.09 ± 0.497
Statistical analysis
  • Double-blind, Vehicle-Controlled (DBVC) Period: Ruxolitinib 1.5% Cream BID vs DBVC Period: Vehicle Cream BID · ANCOVA · p = 0.7982 · Least squares mean difference: 0.19 · 95% CI -1.27 to 1.64
SecondaryChange From Baseline in Itch NRS Score at Week 16

The Itch NRS is a daily participant-reported measure (24-hour recall) of the worst level of itch intensity related to Hidradenitis Suppurativa. The participants rated the itch severity of their Hidradenitis Suppurativa by selecting a number from 0 (no itch) to 10 (worst imaginable itch) that best described their worst level of itching in the past 24 hours. The MMRM included the fixed effects of the treatment group (ruxolitinib 1.5% and vehicle cream), stratification factor (Baseline AN count of ≥3 to 4 or ≥5 to 10), visit, and visit-by-treatment interaction. Change from Baseline was calculated as the Week 16 value minus the Baseline value.

Time frame:
Baseline; Week 16
Reported as:
Least squares mean · scores on a scale
Change From Baseline in Itch NRS Score at Week 16
scores on a scaleDouble-blind, Vehicle-Controlled (DBVC) Period: Ruxolitinib 1.5% Cream BIDDBVC Period: Vehicle Cream BID
Change From Baseline in Itch NRS Score at Week 16-1.45 ± 0.538-2.39 ± 0.493
Statistical analysis
  • Double-blind, Vehicle-Controlled (DBVC) Period: Ruxolitinib 1.5% Cream BID vs DBVC Period: Vehicle Cream BID · ANCOVA · p = 0.2031 · Least squares mean difference: 0.94 · 95% CI -0.52 to 2.40
SecondaryPercentage of Participants Who Achieve Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 16

HiSCR was defined as at least a 50% reduction in AN count with no increase in either abscess or draining fistula counts, relative to Baseline.

Time frame:
Baseline; Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieve Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 16
percentage of participantsDouble-blind, Vehicle-Controlled (DBVC) Period: Ruxolitinib 1.5% Cream BIDDBVC Period: Vehicle Cream BID
Percentage of Participants Who Achieve Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 1679.250.0
SecondaryChange From Baseline in the International Hidradenitis Suppurativa Severity Score System (IHS4) Score at Week 16

The IHS4 is a composite, dynamic score and validated tool used to determine Hidradenitis Suppurativa severity. IHS4 score was calculated by the number of inflammatory nodules (multiplied by 1) plus the number of abscesses (multiplied by 2) plus the number of draining tunnels (multiplied by 4). Scores: mild=0-3; moderate=4-10; severe ≥11. The MMRM included the fixed effects of the treatment group (ruxolitinib 1.5% and vehicle cream), stratification factor (Baseline AN count of ≥3 to 4 or ≥5 to 10), visit, and visit-by-treatment interaction. Change from Baseline was calculated as the Week 16 value minus the Baseline value.

Time frame:
Baseline; Week 16
Reported as:
Least squares mean · scores on a scale
Change From Baseline in the International Hidradenitis Suppurativa Severity Score System (IHS4) Score at Week 16
scores on a scaleDouble-blind, Vehicle-Controlled (DBVC) Period: Ruxolitinib 1.5% Cream BIDDBVC Period: Vehicle Cream BID
Change From Baseline in the International Hidradenitis Suppurativa Severity Score System (IHS4) Score at Week 16-3.58 ± 0.505-2.76 ± 0.459
Statistical analysis
  • Double-blind, Vehicle-Controlled (DBVC) Period: Ruxolitinib 1.5% Cream BID vs DBVC Period: Vehicle Cream BID · ANCOVA · p = 0.2387 · Least squares mean difference: -0.82 · 95% CI -2.20 to 0.56
SecondaryNumber of Participants With Any Treatment-emergent Adverse Event (TEAE ) in the Double-blind, Vehicle-controlled (DBVC) Period

An adverse event (AE) was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it is considered drug related. An AE could therefore have been any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drug. A TEAE was defined as any AE reported for the first time or the worsening of a pre-existing event after the first application of study drug.

Time frame:
up to Week 16 plus 30 days
Reported as:
Count of participants · Participants
Number of Participants With Any Treatment-emergent Adverse Event (TEAE ) in the Double-blind, Vehicle-controlled (DBVC) Period
ParticipantsDouble-blind, Vehicle-Controlled (DBVC) Period: Ruxolitinib 1.5% Cream BIDDBVC Period: Vehicle Cream BID
Number of Participants With Any Treatment-emergent Adverse Event (TEAE ) in the Double-blind, Vehicle-controlled (DBVC) Period1315
SecondaryNumber of Participants With Any Grade 3 or Higher TEAE in the DBVC Period

An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it is considered drug related. A TEAE was defined as any AE reported for the first time or the worsening of a pre-existing event after the first application of study drug. The severity of AEs was assessed using Common Terminology Criteria for Adverse Events (CTCAE) v5.0 Grades 1 through 5. Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; treatment not indicated. Grade 2: moderate; minimal, local, or noninvasive treatment indicated; limiting age-appropriate activities of daily living. Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4: life-threatening consequences; urgent treatment indicated. Grade 5: fatal.

Time frame:
up to Week 16 plus 30 days
Reported as:
Count of participants · Participants
Number of Participants With Any Grade 3 or Higher TEAE in the DBVC Period
ParticipantsDouble-blind, Vehicle-Controlled (DBVC) Period: Ruxolitinib 1.5% Cream BIDDBVC Period: Vehicle Cream BID
Number of Participants With Any Grade 3 or Higher TEAE in the DBVC Period02
SecondaryNumber of Participants With Any TEAE in the Open-label Extension (OLE) Period

An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it is considered drug related. An AE could therefore have been any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drug. A TEAE was defined as any AE reported for the first time or the worsening of a pre-existing event after the first application of study drug.

Time frame:
from Week 17 up to Week 32 plus 30 days
Reported as:
Count of participants · Participants
Number of Participants With Any TEAE in the Open-label Extension (OLE) Period
ParticipantsOLE Period: Ruxolitinib 1.5% Cream BIDOLE Period: Vehicle Cream to Ruxolitinib 1.5% Cream BID
Number of Participants With Any TEAE in the Open-label Extension (OLE) Period815
SecondaryNumber of Participants With Any Grade 3 or Higher TEAE in the OLE Period

An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it is considered drug related. A TEAE was defined as any AE reported for the first time or the worsening of a pre-existing event after the first application of study drug. The severity of AEs was assessed using CTCAE v5.0 Grades 1 through 5. Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; treatment not indicated. Grade 2: moderate; minimal, local, or noninvasive treatment indicated; limiting age-appropriate activities of daily living. Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4: life-threatening consequences; urgent treatment indicated. Grade 5: fatal.

Time frame:
from Week 17 up to Week 32 plus 30 days
Reported as:
Count of participants · Participants
Number of Participants With Any Grade 3 or Higher TEAE in the OLE Period
ParticipantsOLE Period: Ruxolitinib 1.5% Cream BIDOLE Period: Vehicle Cream to Ruxolitinib 1.5% Cream BID
Number of Participants With Any Grade 3 or Higher TEAE in the OLE Period03

Adverse events

Collected over up to Week 32 plus 30 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Vehicle Cream BID0/35 (0%)1/35 (2.9%)2/35 (5.7%)
Ruxolitinib 1.5% Cream BID0/66 (0%)2/66 (3%)5/66 (7.6%)
Most frequent serious events
Most frequent serious events
EventVehicle Cream BIDRuxolitinib 1.5% Cream BID
Diabetic ketoacidosisMetabolism and nutrition disorders1/350/66
Acute kidney injuryRenal and urinary disorders0/351/66
AtelectasisRespiratory, thoracic and mediastinal disorders0/351/66
Crohn's diseaseGastrointestinal disorders0/351/66
Systemic lupus erythematosusMusculoskeletal and connective tissue disorders0/351/66
Most frequent other events
Most frequent other events
EventVehicle Cream BIDRuxolitinib 1.5% Cream BID
NasopharyngitisInfections and infestations0/355/66
NauseaGastrointestinal disorders2/350/66

Baseline characteristics

Age, Continuous
Age, Continuous(years)Double-blind, Vehicle-Controlled (DBVC) Period: Ruxolitinib 1.5% Cream BIDDBVC Period: Vehicle Cream BIDTotal
Mean32.0 ± 9.8331.3 ± 9.8431.7 ± 9.76
Sex: Female, Male
Sex: Female, Male(Participants)Double-blind, Vehicle-Controlled (DBVC) Period: Ruxolitinib 1.5% Cream BIDDBVC Period: Vehicle Cream BIDTotal
Female293362
Male527
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Double-blind, Vehicle-Controlled (DBVC) Period: Ruxolitinib 1.5% Cream BIDDBVC Period: Vehicle Cream BIDTotal
Hispanic or Latino718
Not Hispanic or Latino273461
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Double-blind, Vehicle-Controlled (DBVC) Period: Ruxolitinib 1.5% Cream BIDDBVC Period: Vehicle Cream BIDTotal
White/Caucasian191231
Black/African-American111829
Asian022
Unknown101
Mixed Race: Black and White101
White and American Indian/Alaska Native202
Half White, Half Asian011
Metis, White011
North African011
08

Study locations

20 sites
  • Medical Dermatology Specialists Phoenix
    Phoenix, Arizona 85006, United States
  • First Oc Dermatology
    Fountain Valley, California 92708, United States
  • Skin Care Research, Llc Scr Hollywood
    Boca Raton, Florida 33486, United States
  • Forcare Clinical Research
    Tampa, Florida 33613, United States
  • Marietta Dermatology the Skin Cancer Center Marietta
    Marietta, Georgia 30060-1047, United States
  • Delricht Research
    Baton Rouge, Louisiana 70809, United States
  • Delricht Research
    New Orleans, Louisiana 70115, United States
  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02215, United States
  • Revival Research Institute, Llc Troy
    Troy, Michigan 48084, United States
  • Dr Bobby Buka, Md Greenwich Village
    New York, New York 10012-1354, United States
  • Dermatology Associates of Plymouth Meeting
    Plymouth Meeting, Pennsylvania 19462, United States
  • International Clinical Research Tennessee Llc
    Murfreesboro, Tennessee 37130, United States
  • Austin Institute For Clinical Research Aicr Pflugerville
    Pflugerville, Texas 78660, United States
  • Progressive Clinical Research
    San Antonio, Texas 78213, United States
  • Dermatology Specialists of Spokane
    Spokane, Washington 99202, United States
  • Wiseman Dermatology Research Inc
    Winnipeg, Manitoba R3M 3Z4, Canada
  • Dr.Wei Jing Loo Medicine Professional Corp
    London, Ontario N6H 5L4, Canada
  • Lynderm Research Inc
    Markham, Ontario L3P 1X2, Canada
  • Skin Centre For Dermatology
    Peterborough, Ontario K9J 5K2, Canada
  • Xlr8 Medical Research
    Windsor, Ontario N8W 1E6, Canada
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Incyte shares data with qualified external researchers after a research proposal is submitted. These requests are reviewed and approved by a review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. The trial data availability is according to the criteria and process described on https://www.incyte.com/our-company/compliance-and-transparency

Supporting information: Study protocol, Statistical analysis plan

Time frame: Data will be shared after the primary publication or 2 years after the study has ended for market authorized products and indications.

Access criteria: Data from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.incyteclinicaltrials.com website. For approved requests, the researchers will be granted access to anonymized data under the terms of a data sharing agreement.

Data sharing details ↗ · www.incyte.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2022 to primary completion in Oct 2023, 10 months.

Results were first posted in Nov 2024, 1 year after primary completion.

Of 44 industry-sponsored phase 2 interventional studies under Hidradenitis Suppurativa, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 23. This study's 10 months is below that.

Counting every sponsor, half of 54 studies reached it within 15 months; a quarter within 11 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 23, 2022
First posted
Dec 2, 2022
StartActual
Dec 7, 2022
Primary completionActual
Oct 19, 2023
CompletionActual
Mar 14, 2024
Results first posted
Nov 1, 2024
Last update
Nov 1, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05635838
Lead sponsor
Incyte Corporation
Responsible party
Sponsor
First posted
Dec 2, 2022
Start date
Dec 7, 2022
Primary completion
Oct 19, 2023
Completion
Mar 14, 2024
Results posted
Nov 1, 2024
Last update
Nov 1, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ruxolitinib

Start the discussion